GlassScriptPhysician profile
Dennis C Ryczek
NPI 1447243852
$1,957.56
in general payments reported to CMS, 2019-2025
22 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $239 · 2021: $476 · 2022: $167 · 2023: $218 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $602.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $381.00 | 2019-2021 | |
| Alcon Vision LLC | $312.75 | 2019-2025 | Tryptyr, Rocklatan, Clareon Panoptix Pro |
| Johnson & Johnson Vision Care, INC. | $207.81 | 2019-2022 | |
| Abbvie INC. | $205.07 | 2023 | Xen Glaucoma Treatment System, Durysta |
| Coopervision INC. | $152.59 | 2019-2021 | |
| Amgen INC. | $125.00 | 2025 | |
| Allergan, INC. | $117.87 | 2021 | |
| Glaukos Corporation | $80.50 | 2021-2025 | Idosetr |
| Dompe US, INC. | $52.66 | 2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $45.33 | 2019-2020 | |
| Abb Con-Cise Optical Group LLC | $38.04 | 2019-2020 | |
| Harrow Eye, LLC | $37.55 | 2025 | |
| Rxsight INC | $31.83 | 2022-2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens |
| Sight Sciences, INC. | $25.85 | 2022 | |
| Eyevance Pharmaceuticals LLC | $23.37 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $21.55 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Biotissue Holdings INC. | $18.77 | 2025 | |
| Novartis Pharmaceuticals Corporation | $15.87 | 2019 | |
| Visioneering Technologies, INC. | $15.24 | 2019 | |
| Bausch & Lomb Americas INC. | $15.08 | 2025 | Vyzulta |
| Ocular Therapeutix, INC. | $14.43 | 2025 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Ryczek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.